DEF 14A: PowerUp Acquisition Corp. Seeks Shareholder Approval for Extension and NTA Amendment to Facilitate Business Combination

PowerUp Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination and remove net tangible asset requirements to facilitate a merger with Visiox Pharmaceuticals, Inc.

Summary

• PowerUp Acquisition Corp. is holding an extraordinary general meeting (EGM) on May 17, 2024, to vote on proposals to extend the deadline for completing an initial business combination from May 23, 2024, to February 17, 2025.
• Shareholders will also vote on a proposal to remove the requirement that the company maintain at least $5,000,001 in net tangible assets prior to or upon consummation of a business combination.
• The board believes these changes are necessary to complete a proposed business combination with Visiox Pharmaceuticals, Inc.
• If the extension is approved, shareholders can redeem their shares for a pro-rata portion of the trust account, which held approximately $20,214,049 as of April 30, 2024.
• Failure to approve the extension will result in the company winding up and liquidating, with public shareholders receiving a per-share price from the trust account.
• The initial shareholders, directors, and officers, who own approximately 79.9% of the outstanding ordinary shares, are expected to vote in favor of the proposals.
• The company has engaged Issuer Direct Corporation to assist in the solicitation of proxies for the EGM.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting the facts and proposals for shareholder consideration. While it highlights the potential benefits of the extension and NTA amendment, it also acknowledges the risks and potential negative consequences.

Positives

• The proposed extension provides additional time to complete the business combination with Visiox Pharmaceuticals, potentially offering shareholders an opportunity to participate in a future investment.
• Removing the net tangible asset requirement may facilitate the consummation of the business combination, which might otherwise be hindered.
• Shareholders retain the right to redeem their shares if they do not support the extension or the subsequent business combination.

Negatives

• If the extension is not approved, the company will be forced to liquidate, and the warrants will expire worthless.
• Redemptions in connection with the extension could significantly reduce the amount of funds available in the trust account, potentially requiring the company to seek additional financing.
• If the company redeems its public shares in an amount in excess of the current Redemption Limitation and its securities do not meet Nasdaqs continued listing requirements, Nasdaq may delist the Companys securities from trading on its exchange.

Risks

• There is no assurance that the extension will enable the company to complete an initial business combination.
• Redemptions could leave the company with insufficient cash to consummate a business combination on commercially acceptable terms.
• The SEC's new rules relating to SPACs may increase the company's costs and the time needed to complete its initial business combination.
• The company may be deemed an investment company under the Investment Company Act, which would severely restrict its activities and could lead to liquidation.
• Recent increases in inflation and interest rates could make it more difficult for the company to consummate an initial business combination.
• The excise tax included in the Inflation Reduction Act of 2022 may decrease the amount of funds available for distribution in connection with a liquidation and may hinder the company's ability to consummate an initial business combination.
• If the Extension Amendment Proposal is approved and the company amends its Existing Governing Documents, Nasdaq may delist the company's securities from trading on its exchange following shareholder redemptions in connection with such amendment, which could limit investors ability to make transactions in the company's securities and subject the company to additional trading restrictions.

Future Outlook

The company intends to continue working to consummate an initial business combination by the extended date of February 17, 2025, if the extension amendment proposal is approved.

Management Comments

• The Board believes that it is in the best interests of the shareholders that we continue our existence until the Extended Date in order to allow us more time to complete our initial business combination.
• Our Board believes that it is in the best interests of the shareholders that we remove this requirement in order to facilitate the completion of our initial business combination.

Industry Context

This announcement is typical for SPACs nearing their initial business combination deadline, as they often seek extensions to finalize deals. The proposed removal of the net tangible asset requirement reflects a common strategy to increase flexibility in deal structuring, especially when facing potential redemptions.

Comparison to Industry Standards

• Seeking extensions is a common practice among SPACs approaching their deadlines, reflecting the challenges in finding and closing suitable deals within the initial timeframe.
• The potential for significant redemptions and the need for additional financing are typical concerns for SPACs, especially given recent market volatility and increased regulatory scrutiny.
• Comparable companies that have sought extensions include [hypothetical company A] and [hypothetical company B], which faced similar challenges in completing their initial business combinations.
• The proposed merger with Visiox Pharmaceuticals is similar to other SPAC mergers in the pharmaceutical sector, such as [hypothetical company C]'s merger with [hypothetical company D], which aimed to capitalize on growth opportunities in the healthcare industry.

Stakeholder Impact

• Shareholders have the opportunity to vote on the proposals and redeem their shares if they do not support the extension.
• Employees of PowerUp Acquisition Corp. and Visiox Pharmaceuticals are affected by the potential business combination.
• The outcome of the vote impacts the potential for future investment and growth opportunities.

Next Steps

• Shareholders to vote on the Extension Amendment Proposal, the NTA Proposal, and the Adjournment Proposal at the EGM on May 17, 2024.
• If the Extension Amendment Proposal is approved, the company will continue to work to consummate an initial business combination by February 17, 2025.
• If the Extension Amendment Proposal is not approved, the company will wind up, liquidate, and dissolve.

Key Dates

Keywords

business combination, extension, redemption, net tangible assets, proxy statement, Visiox Pharmaceuticals, liquidation, SPAC, PowerUp Acquisition Corp.